TICKERNERD
Menu
XCURXCURHealthcare · Biotechnology

XCUR Stock Forecast: Exicure, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.00
−1.96% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$7.1M
Ticker Nerd rank
51 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$1.1M
Net income−$1.1M
Free cash flow−$887K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.3%
1M
−29.1%
YTD
−81.5%
1Y
−81.2%
From 52W high
−86.3%
From 52W low
0.0%
$1.00
$7.29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XCUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Exicure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
81
Issuance
70
Growth
61
Volatility
61
Value
40
Quality
37
Revisions
25
Momentum
18

Size (94): Smaller than most of the companies we track.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XCUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XCUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26XCUR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first

Of the 10 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
16 Aug 2022Chardan CapitalMaintainsNeutral$0.25 → $2.00
13 Dec 2021Chardan CapitalDowngradeNeutral$2.25 → $0.40
23 Nov 2021Chardan CapitalMaintainsBuy$7.00 → $2.25
17 May 2021HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
18 Dec 2020BMO CapitalInitiatesOutperform—
17 Sept 2020Chardan CapitalMaintainsBuy$5.00 → $7.00
20 Nov 2019GuggenheimInitiatesBuy—
6 Nov 2019H.C. WainwrightInitiatesBuy—
26 Mar 2019Chardan CapitalInitiatesBuy—
11 July 2018Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XCUR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XCUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Exicure, Inc. returned −81.2% against +16.2% for the S&P 500, dividends included.

XCUR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26XCURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XCUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Exicure, Inc. (XCUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
3.3×

Cheaper than 29% of US stocks

EV / EBITDA
−0.7×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−168.4%

Higher than 9% of US stocks

Return on assets
−30.3%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Exicure, Inc. (XCUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Exicure, Inc. has a market value of $7.1M and an enterprise value of $5.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.4M.

  • Shares outstanding: 6.4M.

  • Trailing P/E: 0.2×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Exicure, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

XCUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XCURExicure, Inc.$7.1M
51
ALZNAlzamend Neuro, Inc.$6.4M
33
EVGNEvogene Ltd.$6.3M
48
LEXXLexaria Bioscience Corp.$6.7M
25
IMNNImunon, Inc.$6.0M
24
NRSNNeurosense Therapeutics Ltd.$6.8M
3
ENVBEnveric Biosciences, Inc.$6.8M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Exicure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XCUR news & analysis

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

GlobeNewsWire · 16 Sept 2026neutral

Exicure, Inc. announced it received a letter from Nasdaq on September 10, 2026, granting the company an extension until December 2, 2026, to regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity. The extension was granted by Nasdaq's Listing Qualifications Department.

Why it matters — The extension gives Exicure additional time to address its stockholders' equity deficiency and avoid potential delisting from the Nasdaq exchange.

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewsWire · 3 Aug 2026neutral

Exicure, Inc. announced it expects to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.

Why it matters — XCUR watchers would note the company is meeting a contractual milestone obligation by issuing equity rather than paying cash, which affects its share count.

FAQ

Frequently asked questions about XCUR stock

Is XCUR stock a buy right now?

Of the 1 analysts covering Exicure, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exicure, Inc. 51 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XCUR?

As at 8 Oct 2026, Exicure, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the XCUR stock forecast for 2030?

No analyst covering Exicure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XCUR are extrapolating price history, which says nothing about the business.

How has XCUR stock performed over the past year?

Exicure, Inc. returned -81.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exicure, Inc. do?

Exicure Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapies and related drug candidates.

What is the latest news on XCUR?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement". Exicure, Inc. announced it received a letter from Nasdaq on September 10, 2026, granting the company an extension until December 2, 2026, to regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity. The extension was granted by Nasdaq's Listing Qualifications Department.

Company

About Exicure, Inc.

Exicure Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapies and related drug candidates. The company uses its proprietary spherical nucleic acid platform to design treatments aimed at validated biological targets, with current work spanning immuno-oncology, inflammatory diseases, genetic disorders, neurological disorders, and hair loss. Exicure’s research and development activities center on advancing RNA-targeted medicines and other therapeutic programs that address conditions with limited treatment options. The company operates as a specialized drug development business within the biotechnology sector, combining in-house discovery capabilities with a platform-based approach to therapeutic design. Exicure Inc. plays a niche role in the market as a developer of next-generation genetic medicine technologies and targeted therapeutics.

CEO Mr. Jungsoo Kim · 1 employees · United States · https://www.exicuretx.com